Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi Sankyo Returns HGF Gene Therapy U.S. And European Rights To AnGes MG

This article was originally published in PharmAsia News

Executive Summary

AnGes MG announced that Daiichi Sankyo, a collaborating partner under an exclusive marketing agreement to develop a gene therapy consisting of plasmid HGF to treat peripheral arterial disease and ischemic heart disease, decided to return the exclusive marketing rights in the U.S. and Europe to AnGes. Daiichi Sankyo will keep the rights in Japan and the two companies still plan to collaborate on launching the drug upon obtaining an approval. An NDA for the plasmid HGF Collategene was filed in Japanin March, 2008. In the U.S. and Europe, AnGes plans to initiate a Phase III trial this year. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC070788

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel